Proteostasis Therapeutics Inc. Secures $45,000,000 Series A Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=cae01090-b167-4989-9cc8-5ba24f16e7c3&Preview=1 -
Date
8/25/2008 -
Company Name
Proteostasis Therapeutics Inc. -
Mailing Address
Undisclosed Cambridge, MA 02138 -
Company Description
Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body’s Proteostasis Network, which maintains the body’s natural protein homeostasis to protect us from numerous diseases. We call these new therapies “Proteostasis RegulatorsTM” and will develop them as novel therapies to treat multiple genetic and degenerative disorders associated with protein homeostasis deficiencies, such as emphysema, type II diabetes, Alzheimer’s Disease and Huntington’s Disease. -
Website
http://www.proteostasis.com -
Transaction Type
Venture Equity -
Transaction Amount
$45,000,000 -
Transaction Round
Series A -
Proceeds Purposes
The funding was done to develop Proteostasis Regulator(TM)Drugs. -
M&A Terms
-
Venture Investor
HealthCare Ventures -
Venture Investor
Fidelity BioSciences -
Venture Investor
New Enterprise Associates -
Venture Investor
Novartis BioVenture Fund -
Venture Investor
Genzyme Ventures
Share
